Adverse event reporting, clinical laboratory tests, vital signs, cardiac monitoring, urinalysis, and clinical monitoring/observation. within 35 days of first dose [clinicaltrials_resource:cb08e5df76201ebddf70bdbc8c806bee]

Adverse event reporting, clinical laboratory tests, vital signs, cardiac monitoring, urinalysis, and clinical monitoring/observation. within 35 days of first dose [clinicaltrials_resource:cb08e5df76201ebddf70bdbc8c806bee]

GSK2251052 500 mg (6 subjects), Placebo (1 subject)
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:cb08e5df76201ebddf70bdbc8c806bee

Adverse event reporting, clinical laboratory tests, vital signs, cardiac monitoring, urinalysis, and clinical monitoring/observation. within 35 days of first dose [clinicaltrials_resource:cb08e5df76201ebddf70bdbc8c806bee]

GSK2251052 500 mg (6 subjects), Placebo (1 subject)
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:cb08e5df76201ebddf70bdbc8c806bee
Bio2RDF identifier
cb08e5df76201ebddf70bdbc8c806bee
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:cb08e5df76201ebddf70bdbc8c806bee
measure [clinicaltrials_vocabulary:measure]
Adverse event reporting, clini ...... inical monitoring/observation.
time frame [clinicaltrials_vocabulary:time-frame]
within 35 days of first dose
description
GSK2251052 500 mg (6 subjects), Placebo (1 subject)
identifier
clinicaltrials_resource:cb08e5df76201ebddf70bdbc8c806bee
title
Adverse event reporting, clini ...... . within 35 days of first dose
@en
inDataset
type
label
Adverse event reporting, clini ...... 8e5df76201ebddf70bdbc8c806bee]
@en